OxThera

OxThera is a biopharmaceutical company that develops Oxabact, an orally administered enteric biotherapy designed to treat Primary Hyperoxaluria. The product works by promoting the active secretion of oxalate from plasma into the gut to be degraded, thereby reducing the oxalate burden on the kidneys. The company focuses on providing treatment options for patients with rare kidney diseases and metabolic disorders.